In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, were welcomed to MHE's first DC Roundtable podcast episode for a discussion on healthcare policy issues.
Murray discussed the impact of Medicaid redetermination on their members, noting significant losses and ongoing challenges.
She emphasized the importance of addressing rate setting and policy flexibility to ensure continuity of care for Medicaid beneficiaries.
Connolly echoed Murray's concerns, emphasizing efforts to ensure individuals rolling off Medicaid maintain insurance coverage, though she expressed further concerns about large for-profit nationals overshadowing nonprofit local plans in Medicaid bidding processes.
Both Murray and Connolly acknowledged the ACA's success in expanding healthcare access but highlighted ongoing affordability challenges and the need for enhanced subsidies.
Regarding partisan divides on the ACA, they stressed the need to separate political "rhetoric" from healthcare benefits.
Despite negative public views on the ACA, many still rely on its provisions for coverage, highlighting the disconnect between public opinion and healthcare needs.
Murray emphasized the need for regulatory changes to strengthen the ACA, stating, "There's still places that the law needs tightening... that's one we'd like to see a permanent codification of the regulation, but even just to get the regulation change from what the previous administration did would be good."
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More